<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="34">
  <!-- This xml conforms to:  http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>Information obtained from ClinicalTrials.gov on October 20, 2011</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01208896</url>
  </required_header>
  <id_info>
    <org_study_id>CHUBX 2009/09</org_study_id>
    <nct_id>NCT01208896</nct_id>
  </id_info>
  <brief_title>Allogeneic Hematopoietic Stem Cell Transplantation After Reduced-intensity Conditioning for Relapsed Follicular Lymphoma</brief_title>
  <acronym>RITALLO</acronym>
  <official_title>Safety and Efficacy of a Strategy of Allogeneic Hematopoietic Stem Cell Transplantation After Reduced-intensity Conditioning for Chemosensitive Relapsed Follicular Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Bordeaux</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Roche Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Bordeaux</source>
  <oversight_info>
    <authority>France: Afssaps - French Health Products Safety Agency</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial will evaluate the efficacy and the safety of a strategy of allogeneic stem cell
      transplantation including Rituximab in the conditioning regimen for the treatment of
      relapsed follicular lymphoma. The rationale for using Rituximab relies on a better control
      of the disease and a better prophylaxis of the graft versus host disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Follicular lymphomas are chemosensitive neoplasms characterized by a relentless succession
      of remissions and relapses when treated with conventional chemotherapy. The successive
      periods of remission are of shorter duration and patients invariably die of their disease.
      At first line, patients are treated with conventional chemotherapy. At first relapse,
      intensive chemotherapy with autologous stem cell transplantation (SCT) is often proposed.

      Allogeneic hematopoietic stem cell transplantation after reduced-intensity conditioning
      (RIC-allo) is an option for patients relapsing after autologous SCT, allowing long-term
      progression free survival of 50 to 60%. The toxic mortality related to severe acute graft
      versus host disease (GVHD) remains a critical issue. The goal of our study is to test in a
      multicentric approach a strategy of RIC-allo including rituximab in order to reduce the
      incidence of acute GVHD.

      Around half of patients with relapsed or refractory follicular lymphomas treated with
      allogeneic SCT achieve long-term progression free survival whatever the conditioning
      regimen. Because the median age of patients with follicular lymphoma is 55 years, a reduced
      intensity conditioning is the most appropriate option in this setting. The outcome of
      patients with a chemoresistant disease is usually poor because of a high toxic mortality. As
      a consequence, only patients with a chemosensitive disease will be included in this study.
      To further reduce the toxic mortality, it is critical to reduce the incidence of severe
      acute GVHD. A low incidence of acute GVHD could be obtained by the use of Rituximab before
      and after the transplantation as reported by the MD Anderson's experience in several
      hematological malignancies including follicular lymphoma. Their results are impressive in
      patients with follicular lymphoma with long-term survival of 85%. The favored hypothesis is
      a depletion of patient and donor B cells reducing the presentation of minor
      histocompatibility alloantigens. The benefit of Rituximab could also be explained by its
      anti-lymphoma effects that could compensate the putative reduction of a graft versus
      lymphoma effect due to a better control of GVHD.

      The primary objective is to estimate 2-year overall survival in this setting.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2011</start_date>
  <completion_date type="Anticipated">October 2015</completion_date>
  <primary_completion_date type="Anticipated">October 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification:  Safety/Efficacy Study, Intervention Model:  Single Group Assignment, Masking:  Open Label, Primary Purpose:  Treatment</study_design>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>2 year</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxic mortality</measure>
    <time_frame>2 year</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>2 year</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of relapse</measure>
    <time_frame>2 year</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Grade II-IV acute GVHD incidence</measure>
    <time_frame>2 year</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chronic GVHD incidence</measure>
    <time_frame>2 year</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morbidity and adverse event</measure>
    <time_frame>2 year</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hematologic reconstitution, Immunologic reconstitution, Chimerism</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">33</enrollment>
  <condition>Lymphoma, Follicular</condition>
  <condition>Stem Cell Transplantation</condition>
  <arm_group>
    <arm_group_label>Rituximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Reduced_intensity conditioning</intervention_name>
    <description>The conditioning regimen is composed of Fludarabine (30 mg/m2) and Cyclophosphamide (750 mg/m2), both administered intravenously at Days -5, -4, -3 with Day 0 being the day of transplantation. Rituximab will be administered intravenously at 375 mg/m2 at Day -13 and 1000 mg/m2 at Days -6, +1, +8. Tacrolimus and low-doses of methotrexate will be used for prophylaxis of GVHD.</description>
    <arm_group_label>Rituximab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 and ≤ 65 years

          -  Follicular lymphoma confirmed by a biopsy at the last relapse.

          -  3rd or 4th complete or partial response according to Cheson's criteria 1 (Annexe 1)

          -  Relapse after autologous-SCT except if the absence of autologous SCT is due to a
             failure of collecting peripheral stem cells

          -  Relapse after at least one line of treatment with rituximab

          -  Karnofsky index &gt; 70%

          -  HLA Matched related or unrelated donor (10/10 matching; HLA-A, HLA-B, HLA-C,
             HLA-DRB1, HLA-DQB1)

          -  Signed informed consent

        Exclusion Criteria:

          -  Stable or progressive disease according to Cheson's criteria1 (Annexe 1)

          -  Absence of treatment with rituximab before the last relapse

          -  Cardiac insufficiency (ejection fraction &lt; 50% by echocardiography)

          -  Pulmonary disease characterized by DLCO &lt; 60%

          -  Renal insufficiency (clearance of creatinin &lt; 60 ml/min)

          -  Hepatic disease characterized by ASAT and/or ALAT and/or total bilirubin &gt; 2 times
             the upper normal value except in case of Gilbert's disease or hepatic lymphoma

          -  HIV positive test

          -  Bacterial, Viral or Fungal uncontrolled infections

          -  Pregnant or breast feeding woman

          -  Cancer in the last 5 years except in case of cutaneous baso-cellular cancer or
             epithelioma &quot;in situ&quot; of the uterine cervix
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stéphane VIGOUROUX, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Bordeaux</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Adélaïde DOUSSAU, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital, Bordeaux</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stéphane VIGOUROUX, MD</last_name>
    <phone>(33)5 57 65 65 11</phone>
    <email>stephane.vigouroux@chu-bordeaux.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Cyril MELOT, CRA</last_name>
    <phone>(33)5 57 65 65 11</phone>
    <email>cyril.melot@chu-bordeaux.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Angers</name>
      <address>
        <city>Angers Cedex 01</city>
        <state>Angers</state>
        <zip>49033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martine GARDEMBAS-PAIN, Dr</last_name>
      <phone>02.41.35.47.05</phone>
      <email>MaGardembas@chu-angers.fr</email>
    </contact>
    <investigator>
      <last_name>GUARDIOLAT, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>FRANCOIS, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service Hématologie, Hôpital Minjoz</name>
      <address>
        <city>Besançon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Eric DECONINCK</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fabrice LAROSA, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Katell LE DU, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fatémeh LEGRAND-IZADIFAR, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service des maladies du sang - Hôpital Haut-Lévêque - avenue de magellan</name>
      <address>
        <city>Bordeaux - Pessac</city>
        <zip>33600</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Krimo BOUABDALLAH, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Noel MILPIED</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Reza TABRIZI</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stephane VIGOUROUX</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service Hématologie, Hôpital Augustin Morvan</name>
      <address>
        <city>Brest</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Christian BERTHOU</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gaëlle GUILLERM</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital, Caen</name>
      <address>
        <city>Caen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Oumedaly REMAN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stephane CHEZE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Margaret MACRO, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hyacinthe JOHNSON-ANSAH, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Khaled BANABED, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sylvain CHANTEPIE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michel LEPORRIER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service Hématologie et Thérapie cellulaire, Pavillon Villemin Pasteur, CHU Clermont-Ferrand</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Olivier TOURNILHAC</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carine CHALETEIX</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Benoit de RENZIS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eric HERMET</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jacques-Olivier BAY, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Romain GUIEZE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Victoria CACHEUX, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Grenoble</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claude-eric BULABOIS</last_name>
    </contact>
    <investigator>
      <last_name>Claude-Eric BULABOIS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU Lille</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ibrahim YAKOUB-AGHA</last_name>
    </contact>
    <investigator>
      <last_name>Ibrahim YAKOUB-AGHA</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Limoges</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pascal TURLURE</last_name>
    </contact>
    <investigator>
      <last_name>Pascal TURLURE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Edouard Herriot</name>
      <address>
        <city>Lyon</city>
        <zip>69374</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mauricette MICHALLET, MD</last_name>
      <phone>04 72 11 74 01</phone>
      <email>mauricette.michallet@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>Mauricette MICHALLET, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Franck NICOLINI, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xavier-Georges THOMAS, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sophie DUCASTELLE-LEPRETRE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Giovanna CANNAS, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fiorenza BARRACO, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nicolae Claudiu PLESA, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Emmanuelle NICOLAS-VIRELIZIER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service Hématologie Oncologie, Hôpital Lapeyronie, CHU de Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Nathalie FEGUEUX</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Patrice CEBALLOS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-François ROSSI</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean Côme MENIANE</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Nancy</name>
      <address>
        <city>Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre FEUGIER</last_name>
    </contact>
    <investigator>
      <last_name>Pierre FEUGIER</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service Hématologie Clinique, CHU -Hôtel Dieu</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Patrice CHEVALLIER</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thierry GUILLAUME</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mohamad MOHTY, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service Hématologie Clinique, Hôpital Archet 1</name>
      <address>
        <city>Nice</city>
        <zip>06202</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Anne SIRVENT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nicole GRATECOS, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nicolas MOUNIER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>APHP Hôpital Saint Louis</name>
      <address>
        <city>Paris</city>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gérard SOCIE</last_name>
    </contact>
    <investigator>
      <last_name>Gérard SOCIE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>APHP Hôpital Henri-Mondor</name>
      <address>
        <city>Paris</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Corinne HAOUIN</last_name>
    </contact>
    <investigator>
      <last_name>Corinne HAOUIN</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>APHP Hôpital Necker-Enfants malades</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Agnès BUZYN</last_name>
    </contact>
    <investigator>
      <last_name>Agnès BUZYN</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>APHP Hôpital Pitié-Salpêtrière</name>
      <address>
        <city>Paris</city>
        <zip>75651</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nathalie DHEDIN</last_name>
    </contact>
    <investigator>
      <last_name>Nathalie DHEDIN</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Poitiers - La Milétrie</name>
      <address>
        <city>Poitiers</city>
        <zip>86000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Natacha MAILLARD</last_name>
    </contact>
    <investigator>
      <last_name>Natacha MAILLARD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service Hématologie Clinique, Hôpital Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Thierry LAMY DE LA CHAPELLE</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Charles Dauriac</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Martine Escoffre-Barbe</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marc Bernard</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sophie De Guibert</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stanislas NIMUBONA</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Henri Becquerel</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hervé TILLY</last_name>
    </contact>
    <investigator>
      <last_name>Hervé TILLY</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de la Loire</name>
      <address>
        <city>Saint Etienne</city>
        <zip>60008</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jerôme CORNILLON</last_name>
    </contact>
    <investigator>
      <last_name>Jérôme CORNILLON</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Département d'Hématologie et d'Oncologie, Hôpital CHRU de Hautepierre</name>
      <address>
        <city>Strasbourg</city>
        <zip>67098</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Bruno LIOURE</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Karin BILGER</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Luc-Matthieu FORNECKER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service Hématologie, Hôpital Purpan</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Anne HUYNH</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Murielle ROUSSEL</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU Tours</name>
      <address>
        <city>Tours</city>
        <zip>37000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Séverine LISSANDRE</last_name>
    </contact>
    <investigator>
      <last_name>Séverine LISSANDRE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Vincent RIBRAG</last_name>
    </contact>
    <investigator>
      <last_name>Vincent RIBRAG</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, Coiffier B, Fisher RI, Hagenbeek A, Zucca E, Rosen ST, Stroobants S, Lister TA, Hoppe RT, Dreyling M, Tobinai K, Vose JM, Connors JM, Federico M, Diehl V; The International Harmonization Project on Lymphoma. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007 Feb 10;25(5):579-86. Epub 2007 Jan 22.</citation>
    <PMID>17242396</PMID>
  </reference>
  <reference>
    <citation>Khouri IF, Saliba RM, Giralt SA, Lee MS, Okoroji GJ, Hagemeister FB, Korbling M, Younes A, Ippoliti C, Gajewski JL, McLaughlin P, Anderlini P, Donato ML, Cabanillas FF, Champlin RE. Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality. Blood. 2001 Dec 15;98(13):3595-9.</citation>
    <PMID>11739162</PMID>
  </reference>
  <reference>
    <citation>Khouri IF, McLaughlin P, Saliba RM, Hosing C, Korbling M, Lee MS, Medeiros LJ, Fayad L, Samaniego F, Alousi A, Anderlini P, Couriel D, de Lima M, Giralt S, Neelapu SS, Ueno NT, Samuels BI, Hagemeister F, Kwak LW, Champlin RE. Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab. Blood. 2008 Jun 15;111(12):5530-6. Epub 2008 Apr 14. Erratum in: Blood. 2009 Feb 12;113(7):1613.</citation>
    <PMID>18411419</PMID>
  </reference>
  <reference>
    <citation>Vigouroux S, Michallet M, Porcher R, Attal M, Ades L, Bernard M, Blaise D, Tabrizi R, Garban F, Cassuto JP, Chevalier P, Facon T, Ifrah N, Renaud M, Tilly H, Vernant JP, Kuentz M, Bourhis JH, Bordigoni P, Deconinck E, Lioure B, Socié G, Milpied N; French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC). Long-term outcomes after reduced-intensity conditioning allogeneic stem cell transplantation for low-grade lymphoma: a survey by the French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC). Haematologica. 2007 May;92(5):627-34.</citation>
    <PMID>17488686</PMID>
  </reference>
  <reference>
    <citation>Christopeit M, Schütte V, Theurich S, Weber T, Grothe W, Behre G. Rituximab reduces the incidence of acute graft-versus-host disease. Blood. 2009 Mar 26;113(13):3130-1. No abstract available.</citation>
    <PMID>19324911</PMID>
  </reference>
  <verification_date>April 2011</verification_date>
  <lastchanged_date>April 26, 2011</lastchanged_date>
  <firstreceived_date>September 23, 2010</firstreceived_date>
  <responsible_party>
    <name_title>Jean-Pierre LEROY / Clinical Research and Innovation Director</name_title>
    <organization>University Hospital, Bordeaux</organization>
  </responsible_party>
  <keyword>Allogeneic hematopoietic stem cell transplantation</keyword>
  <keyword>Reduced-intensity conditioning</keyword>
  <keyword>Chemosensitive relapsed follicular lymphoma</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Follicular</mesh_term>
  </condition_browse>
</clinical_study>
